From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from rat)
Targetβ7 subunit of α4β7 and αEβ7 integrin heterodimers
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
CAS Number
  • none
Chemical and physical data
Molar mass144.1 kg/mol
 ‹See TfM›☒N☑Y (what is this?)  (verify)

Etrolizumab (rhuMAb Beta7) is a biopharmaceutical drug candidate being developed for the treatment of ulcerative colitis and Crohn's disease. It is a humanized monoclonal antibody against the β7 subunit of integrins α4β7 and αEβ7.[1] Etrolizumab was developed by Genentech[2] by engineering the FIB504 antibody to include human IgGl-heavy chain and κ-light chain frameworks; it is manufactured in CHO cells.[3]

As of 2016 it was in phase III studies for induction and maintenance therapy in people with ulcerative colitis and Crohn's.[2][4][5]


  1. ^ Adis Insight Etrolizumab Latest Information Update: 16 Dec 2015
  2. ^ a b UK Medicines Information. etrolizumab at UKMI Page accessed May 10, 2016
  3. ^ Published PCT application WO2012135589, "Methods of administering beta7 integrin antagonists," assigned to Genentech and Roche. Paragraph 146. For the FIB504 mAb, see Andrew DP et al. Distinct but overlapping epitopes are involved in alpha 4 beta 7-mediated adhesion to vascular cell adhesion molecule-1, mucosal addressin-1, fibronectin, and lymphocyte aggregation. J Immunol. 1994 Nov 1;153(9):3847-61. PMID 7523506 as referenced in paragraph 146 of the PCT application.
  4. ^ Makker J, Hommes DW. Etrolizumab for ulcerative colitis: the new kid on the block? Expert Opin Biol Ther. 2016 Apr;16(4):567-72. PMID 26914639
  5. ^ Rosenfeld G et al. Etrolizumab for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015 Dec 2;12:CD011661. PMID 26630451